News
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...
Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...
The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...
OrderlyMeds fights back after Big Pharma crackdown, igniting a battle over the future of personalized medicine ...
To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...
Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...
BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback